ArticleACG case reports journal2025
Lipoprotein X-Induced Hyperlipidemia Following Liver Transplantation in the Setting of Persistent Cholestasis and Antibody-Mediated Rejection.
Article in ACG case reports journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipoprotein X (Lp-X) is an abnormal lipoprotein that accumulates in the setting of cholestasis, leading to marked hypercholesterolemia, lipid deposition, and hyperviscosity-related complications. While well described in primary biliary cholangitis and primary sclerosing cholangitis, Lp-X has rarely been reported following liver transplantation. We describe a liver transplant recipient who developed severe Lp-X hyperlipidemia secondary to persistent cholestasis from an early post-transplant anastomotic stricture compounded by antibody-mediated rejection. Despite plasmapheresis and immunosuppressive therapy, his cholestasis and hyperlipidemia persisted, and his course was complicated by seizures and acute kidney injury. He was evaluated for retransplantation but ultimately died of septic shock. This case highlights the importance of recognizing Lp-X as a marker of significant biliary dysfunction post-transplant and the need for targeted interventions to prevent progressive end-organ injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.